- Reuters•9 minutes ago
The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies. Sanofi and Regeneron said the drug, Dupixent, will have a list price of $37,000 a year. "We are encouraged by the ongoing conversations we've had with health plans and pharmacy benefit managers about coverage for Dupixent for patients," Sanofi said in a statement.
- The Wall Street Journal•1 hour ago
Regeneron Pharmaceuticals and Sanofi said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy ...
- American City Business Journals•1 hour ago
The FDA has approved a drug to treat eczema made by Cambridge-based Sanofi Genzyme that some analysts believe could eventually surpass $3 billion in annual sales. The agency announced Tuesday that it has approved dupilumab, a treatment for atopic dermatitis that will be sold under the brand name Dupixent. The drug was developed by Sanofi Genzyme, a division of French pharmaceutical giant Sanofi SA (SNY), along with its partner Regeneron Pharmaceuticals (REGN).
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||45.18 - 45.95|
|52 Week Range||36.81 - 45.95|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.45|
|Dividend & Yield||1.58 (3.53%)|
|1y Target Est||N/A|